Original Scientific Articles
Download PDF (266.61 KB)
Journal of Structural Heart Disease, February 2016, Volume 2, Issue 1:33-34
DOI: 10.12945/j.jshd.2016.012.14
Current Status of Percutaneous Pulmonic Valve Therapies: The Melody Valve
Marc Gewillig, MD, PhD, FAEPC, FESC, FACC
Pediatric Cardiology, Leuven University, UZ Leuven, Herestraat 49, Leuven, Belgium
Abstract
Transcatheter percutaneous pulmonary valve implantation (PPVI) was first described in 2000 by Philip Bonhoeffer et al 1 as an alternative to open-heart surgery to prolong survival of a right ventricular outflow tract (RVOT) valve conduit.
Since then multiple studies have documented the short term benefits of PPVI implantation using the Melody™ valved stent (Medtronic Inc, Minneapolis, USA) for dysfunctional right ventricle to pulmonary artery (RV-AP) conduits.
This review discusses the development, current status and future endeavors of the Melody valve in the pulmonic position.
Media
Video 1
PPVI: PO Fallot. 6F Multitrack over 0.035” E-wire; shrunken 25 mm homograft
Video 2
PPVI: PO Fallot. 6F Multitrack over 0.035” E-wire; shrunken 25 mm homograft
Video 3
PPVI: PO Fallot. Interrogate with 20 mm balloon over 0.035” E-wire; Ao root angiogram
Video 4
PPVI: PO Fallot. Interrogate with 20 mm balloon over 0.035” E-wire; Ao root angiogram
Video 5
PPVI: PO Fallot. 45 mm CCP stent on 24 mm BIB through 14 F Cook sheath
Video 6
PPVI: PO Fallot. 45 mm CCP stent on 24 mm BIB through 14 F Cook sheath
Video 7
PPVI: PO Fallot. Control angiogram through 14 F sheath.
Video 8
PPVI: PO Fallot. Control selective angiogram: ? LAD
Video 9
PPVI: PO Fallot. Control selective angiogram: ? LAD
Video 10
PPVI: PO Fallot. Dilation with 22 mm Atlas Gold up to 20 atm.
Video 11
PPVI: PO Fallot. Control selective LCA angiogram: ? LAD
Video 12
PPVI: PO Fallot. PPVI of Melody with 22 mm Ensemble
Cite this article as: Gewillig M. Current Status of Percutaneous Pulmonic Valve Therapies: The Melody Valve. Structural Heart Disease 2016;2(1):33-34. DOI: 10.12945/j.jshd.2016.012.14
All comments will be screened and reviewed before posting. Statements, opinions, and results of studies published in Journal of Structural Heart Disease are those of the authors and do not reflect the policy or position of The Journal and Science International and the Editorial Board and provides no warranty as to their accuracy or reliability. Material is copyrighted and owned by Science International and cannot be used without expressed permission.
Original Scientific Articles
Download PDF (266.61 KB)
Journal of Structural Heart Disease, February 2016, Volume 2, Issue 1:33-34
DOI: 10.12945/j.jshd.2016.012.14
Current Status of Percutaneous Pulmonic Valve Therapies: The Melody Valve
Marc Gewillig, MD, PhD, FAEPC, FESC, FACC
Pediatric Cardiology, Leuven University, UZ Leuven, Herestraat 49, Leuven, Belgium
Abstract
Transcatheter percutaneous pulmonary valve implantation (PPVI) was first described in 2000 by Philip Bonhoeffer et al 1 as an alternative to open-heart surgery to prolong survival of a right ventricular outflow tract (RVOT) valve conduit.
Since then multiple studies have documented the short term benefits of PPVI implantation using the Melody™ valved stent (Medtronic Inc, Minneapolis, USA) for dysfunctional right ventricle to pulmonary artery (RV-AP) conduits.
This review discusses the development, current status and future endeavors of the Melody valve in the pulmonic position.
Media
Video 1
Video 2
Video 3
Video 4
Video 5
Video 6
Video 7
Video 8
Video 9
Video 10
Video 11
Video 12
PDF
Download the article PDF (266.61 KB)
Download the full issue PDF (38.51 MB)
Mobile-ready Flipbook
View the full issue as a flipbook (Desktop and Mobile-ready)
Cite this article as: Gewillig M. Current Status of Percutaneous Pulmonic Valve Therapies: The Melody Valve. Structural Heart Disease 2016;2(1):33-34. DOI: 10.12945/j.jshd.2016.012.14
You must be registered and logged in to leave comments.
There have been no comments posted yet
Ask a question (publicly)
Board